Inhaled or IV? study tests best way to clear mucus in bronchiectasis
NCT ID NCT07293884
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will compare two methods of giving N-acetylcysteine—a drug that thins mucus—to 70 adults hospitalized with bronchiectasis. Half will receive the drug through a nebulizer (inhaled), and half through an IV. Researchers will measure how well each method reduces sputum thickness, amount, and difficulty coughing it up. The goal is to find which route works better for airway clearance.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- N-acetylcysteine
- What this could lead to
- If it works, this could show that one method of giving N-acetylcysteine is better at clearing mucus and making breathing easier for people with bronchiectasis.
- What could go wrong
- This is a small, early-stage study with only 70 people. It may not find a clear difference between the two methods, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Apr 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects aged above 18 years old; with a diagnosis of bronchiectasis who are admitted to chest department due to acute exacerbation Exclusion Criteria: * current smokers, a known allergy to N-acetylcysteine; pregnancy or lactation (for women); primary diagnosis of COPD or asthma
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Broncheictasis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.